Sirona Biochem Announces Positive Results of PK Study for Type 2 Diabetes
Vancouver, British Columbia – September 3, 2014 – Sirona Biochem Corp. (TSX-V: SBM.V FSE: ZSB) today announced that Wanbang Biopharmaceuticals has successfully completed another study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes.
The pharmacokinetic (PK) study of SBM-TFC-039 confirms an excellent oral bioavailability of SBM-TFC-039. Bioavailability refers to the drug’s ability to be absorbed into the body. The results are in accordance with results of an earlier study conducted by Sirona Biochem. The drug was administered as a single dose in SD rats. The first milestone of the license agreement with Wanbang Biopharmaceuticals is expected after the next scheduled study, assessing toxicology in rats during a 14 day test. This will trigger a second payment to Sirona from Wanbang Biopharmaceuticals as part of the $9.5M in upfront and milestone payments.
“These results provide further evidence that we have an excellent compound for the treatment of Type 2 diabetes”, said Dr. Howard Verrico, CEO. “Good bioavailability of a drug equates to lower dosing. It’s a win for us in terms of the development of our SGLT2 Inhibitor.”
About Wanbang Biopharmaceuticals
Wanbang Biopharmaceuticals is the leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes.
Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group which is listed on the Shanghai Stock Exchange. Fosun Pharma, one of the major shareholders of Sinopharm Group, the largest drug distributor in China, is part of Fosun International, the leading non-state owned enterprise group in China which is listed on the Hong Kong Stock Exchange.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Blog
OrganiGram ships first medical marijuana orders
ORGANIGRAM PASSES PRODUCT TESTING AND SHIPS MEDICAL MARIJUANA TO CUSTOMERS
OrganiGram Holdings Inc. has shipped its first orders of medical marijuana to customers.
The product being shipped was sent to RPC Laboratory to undergo product testing as per Health Canada guidelines. The company has received the results of said testing that confirm the product to be in conformance with the Health Canada marijuana for medical purposes regulations (MMPR).
Chief executive officer Denis Arsenault states: “We are extremely pleased to have passed testing and shipped product to our first customers. The fact that we were able to produce product that passed testing without the process of irradiation (cold pasteurization) confirms the high quality of our team, facility and validated the benefits of our organic growing process.”
d
- Published in Medical Marijuana
The best college for every major
In many cases, a worker’s paycheck will have more to do with the major they chose than the school that granted them a diploma, but experts say prospective students should look at both.
In a study released Thursday, PayScale, a provider of compensation data and software, created a list of the best schools for each college major. The firm surveyed 1.4 million college graduates with bachelor’s degrees about their degrees and earnings and found that even students choosing less lucrative majors like English may have a better chance of landing a higher-paying job if they attend a particular school. “There will be differences in earnings by majors and by school, and they are substantial,” says Anthony Carnevale, director of the Georgetown University Center on Education. “You need to be informed,” he says, adding that students considering a certain program should also turn to professors and former students for guidance.
Video: The best college for every major
To be sure, the reasons behind the differences weren’t clear, and researchers pointed out that the list ranking the best schools for each major excluded many small and liberal arts schools. That said, here is a look at some of the best paying schools for each college major.
— By Jonnelle Marte
- Published in Blog
California marijuana market poised to explode
Looking around last week at the exhibitor showroom of CannaCon, the huge marijuana-business expo held outside Seattle, Greg James had something of an epiphany: The pot industry in America is growing like, you guessed it, a weed.
“There was everybody from soil companies to grow-light companies to lawyers and security and insurance firms to a TV network doing shows just on marijuana,” said James, whose Seattle-based Marijuana Venture newsletter has exploded from eight to 84 glossy pages since it launched in March and is already turning a profit. “I’m not sure how many of them will survive, but it’s amazing how fast this thing is moving.”
The legal pot business in the United States, including both the newly legalized retail operations in Washington and Colorado and the medical-marijuana use now allowed in California and 22 other states, is expected to grow this year to $2.6 billion from $1.5 billion in 2013, according to the ArcView Group, a San Francisco-based marijuana research and investment firm. In five years, that number could swell to more than $10 billion. And if backers are successful in getting a legalization measure on the 2016 ballot in California, the Golden State, with its already outsize medical-pot market, could soon be entering a Golden Era of commercialized cannabis.
Although the state in 1996 became the first in the nation to legalize pot for medicinal reasons, California has yet to approve it for the overall adult population, or so-called “adult-use.” Despite that, it has the largest pot market in the nation, according to a widely referenced report last year by ArcView.
“California remains the largest state market at $980 million, even without Adult Use regulations,” said the report. And “once Adult Use is adopted — which is likely by 2017 — the total California market is projected to increase dramatically.”
As marijuana use has become more mainstream, a veritable smorgasbord of professionals and young startups has popped up to feed off and support the pot culture. Lawyers, accountants and real-estate brokers are going after pot clients like hogs to truffles. There are security outfits protecting Mendocino County farms and software developers churning out cannabis-news apps and GPS-enabled tools like Weedly to find the nearest pot club. And there are even pot-friendly resorts where the Hollywood set can go to get high in peace, provided they have a prescription.
“I’ve worked with Cameron Diaz and Justin Timberlake, who can’t go to traditional dispensaries, so we have a resort outside Grass Valley as a place for them to get away,” says Cheryl Shuman, the self-styled “Martha Stewart of Marijuana” who has delivered her pro-pot mantra to “Good Morning America” and anyone else who’ll listen. “We also have mansion parties in L.A. with chefs from five-star restaurants; it’s just like wine-tasting dinners, but you pair different strains of cannabis with the food.”
Still, the pot business is a long way from maturity, despite the already impressive amount of cash it’s generating.
“It’s still a sort of fragmented cottage industry, so the laws still have to change and allow for entrepreneurs to push this business forward,” says former investment banker Derek Peterson, who co-founded Blum Oakland, a medical cannabis dispensary, in 2012 and has seen 35 percent year-over-year growth. He figures that just a few of the dispensaries in the East Bay do a combined $50 million in revenues each year.
David Hodges, who runs the All American Cannabis Club in San Jose, says that while it’s hard to get a solid grasp of the industry’s size, he estimates San Jose alone hosts a $60-million-a-year medical-marijuana business and that the black market is three times that, for a combined value of about $240 million in his city alone.
By Peterson’s estimate, the overall legal Bay Area pot market is roughly equal in size to Colorado’s, which analysts predict will be about $253 million this year.
Even though California’s current medical-marijuana industry is riddled with conflicting laws and policies that can differ city by city, with some pot clubs paying taxes and others not, the business is booming with no sign of letting up. Nate Bradley, an ex-cop and executive director of the California Cannabis Industry Association, says an estimated 100,000 Californians already are employed in the industry, either growing pot or servicing suppliers and their customers, a number that would soar with legalization.
“Once the medical-marijuana industry is legalized statewide, and you legitimize the entire production and distribution of medical cannabis,” says Bradley, “the business will explode and the state would collect $400 million a year or more in sales taxes.”
In the meantime, companies large and small are lining up to grab a piece of the cannabis action. Eaze, a San Francisco startup that fancies itself as “the Uber of medical cannabis delivery,” taps into a network of “caregivers” who pick up pot for you at the dispensary and deliver it to your home, sometimes within 10 minutes.
Eddie Bernard runs a pot-focused marketing agency in Southern California that worked with High Times magazine on its first Cannabis Cup competition in America, with awards going to the best pot varieties. He also does “product placement” for the marijuana industry.
“We did an endorsement deal with Snoop Dogg,” says Bernard, “and for an FX TV show we placed bongs around the house.”
Yet even as more and more entrepreneurs jump into the pot business, the path forward is far from clear. Despite strong revenues and taxes already being collected in Washington and Colorado, the industry faces years of political and regulatory challenges. At the top of the list are federal laws declaring the possession, sale and cultivation of pot illegal, leaving states and the federal government in an awkward standoff. Public opinion on legalization is also split. And a sprawling and powerful black market thrives in the shadows, while groups on both sides of the legalization debate bicker among themselves.
Still, many aspiring business owners are convinced that a pot-based gold rush is upon us. To former Intuit engineer Ben Curren, his new San Jose-based tech startup, Green Bits, is at the right place at the right time, offering point-of-sale and inventory management software for the legal pot industry.
“2016 will be the deciding year,” says Curren. “But it’s amazing how much stuff is happening in this space right now. If the momentum continues, this is going to be really big.”
- Published in Blog
Lakeland finishes sampling, mapping program at Star
LAKELAND RESOURCES INC. PROVIDES UPDATE ON 2014 EXPLORATION
Lakeland Resources Inc. is providing an update on recent and planned work at its 100-per-cent-owned Athabasca basin uranium properties.
Highlights
- Star uranium property: completion of follow-up mapping and prospecting at the Star uranium property. This work was completed in order to define the deposit model and the source of the gold, Platinum group element (PGE) and rare earth element (REE) mineralization observed during the fall of 2013;
- Lazy Edward Bay property: exploration permits have been received for the proposed summer work program and crews will begin mobilization to the property as soon as possible. The BAY trend will be the focus of exploration;
- Fond Du Lac property: exploration permits have been received for the proposed summer work program and crews will begin mobilization to the property as soon as possible. The Fond du Lac property is targeting a coincident geochemical and conductive target at the margin of the Athabasca basin.
Star uranium property
Crews from Dahrouge Geological Consulting Ltd. recently completed a six-day sampling and mapping campaign at the Star uranium property. A total of 73 rock samples and 124 soil samples were collected from in and around the uplifted basement block at the northeastern portion of the property, immediately north of the margin of the Athabasca basin. This work was completed in order to define the deposit model and the source of the gold, platinum group element and rare earth element results obtained in the fall of 2013. The 2013 sampling explored a small portion of the uplifted basement outcrop on the Star property. Anomalous concentrations of gold (up to 5.7 grams per tonne gold), platinum group elements (0.75 g/t PGE), rare earth elements (up to 6.9 per cent total rare earth oxides (TREO)) and highly anomalous uranium suggest the presence of a robust hydrothermal system.
Lazy Edward Bay property
Exploration permits have been received for the proposed summer work program, and mobilization to the property will begin as soon as possible. The BAY trend will be tested with a RadonEX survey. This and other targets will be prospected in order to locate boulders or other surface expressions of shallow unconformity-style uranium mineralization.
The BAY trend consists of two parallel conductive trends at the southern margin of the Athabasca basin. The BAY trend is highlighted by historic exploration of Uranerz in 1982, where drill hole LE-50 intersected the basement rocks about one kilometre south of the Athabasca sandstones. Moderately chloritized, sericitized and weakly hematized migmatitic, graphitic pelite returned an assay value of 770 parts per million uranium along with anomalous boron, nickel, pathfinder metals (Sask AR: 74G07-0042).
Fond Du Lac property
Exploration permits have been received for the proposed summer work program, and crews will begin mobilization to the property as soon as possible. The Fond du Lac property is targeting a coincident geochemical and conductive target at the margin of the Athabasca basin.
National Instrument 43-101 disclosure
The technical information above has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 and reviewed on behalf of the company by Neil McCallum, PGeo, of Dahrouge Geological Consulting Ltd., a qualified person.
- Published in Mining
Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project
VANCOUVER, BC–(Marketwired – August 12, 2014) – Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the “Company”) announced that its French subsidiary, TFChem, has received confirmation for funding of CDN$1.2 million from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie in the form of a no-interest loan. The funds will be used to advance the organization’s anti-aging project.
The loan, co-funded by Bpifrance and the district of Haute Normandie, will be dispersed in lump sums and is strictly allocated for advancement of the anti-aging compounds into preclinical testing. Repayment of the loan will be made in installments, beginning in Q3 2018 with the majority being paid after 2020. The company expects to be into substantial milestone and royalty payments before any repayment of the loan begins.
“With the tremendous support provided by this loan the need to arrange financings over the next 12 to 18 months are anticipated to be minimal,” reports CEO and Chairman of Sirona Biochem, Dr. Howard Verrico. “The funding received from Bpifrance and the district of Haute Normandie will enable us to start testing our library of anti-aging compounds without dilution. We are very excited about the potential of these compounds and the interest shown in them.”
The global anti-aging product market is currently valued at over $220 Billion USD with a CAGR of 5.2{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}. It’s expected to be nearly $285 Billion USD by the year 2018.1
About Sirona Biochem and TFChem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com or www.tfchemistry.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Life Sciences
Sirona Biochem Launches Global Awareness Campaign With Cousteau Ambassadors’ Video
VANCOUVER, BC, Aug 21, 2014 (Marketwired via COMTEX) — Sirona Biochem Corp. (SBM) (frankfurt:ZSB) launches global awareness campaign with ambassadors’ video produced by the team of Jean-Michel Cousteau and Fabien Cousteau to represent their support of the glycoprotein project.
“The time and effort put into this video illustrates just how dedicated the Cousteaus are to the relationship with Sirona Biochem,” said Howard Verrico, founder and CEO. “Having Jean-Michel and Fabien’s support for this project serves as a reminder of the immense potential value in these compounds.”
Jean-Michel Cousteau and Fabien Cousteau (son and grandson of Jacques Cousteau) are brand ambassadors for Sirona’s glycoprotein project. The project has also been generously supported by Bpifrance (the French Public Investment Bank) and the district of Haute Normandie with funding of CDN$1.2 million in the form of a no-interest loan.
The video can be viewed at the following link: http://youtu.be/s0PDhFOl6Ck
(with German subtitles: http://youtu.be/j5LDgIyzC3Y)
Sirona Biochem also announces attendance at the upcoming BIO Europe conference in Frankfurt Germany Nov 3-5 2014 with support from BIOTECanada and the Canadian Trade Commissioner Service, Global Opportunities for Associations (GOA) program.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
- Published in Life Sciences
Soros Doubles YPF Stake in Argentina’s Nascent Shale Boom
George Soros’s $28 billion family office more than doubled its stake in YPF SA, making the state-controlled oil producer its biggest U.S.-traded stock holding two years after Argentina seized control of the company.
Soros Fund Management LLC added 8.47 million shares of YPF in the second quarter, according to a filing yesterday, bringing its position to 3.5 percent of the American depositary receipts. That was worth $450 million at the end of June, making Soros the fourth-biggest holder. The stock rallied today. click here to read the full article – http://www.bloomberg.com/news/2014-08-14/soros-adds-to-ypf-trims-teva-exits-monster-in-quarter.html
- Published in Blog
How job recruiters screen you on LinkedIn
There are 277 million users on LinkedIn, according to the company’s latest results, and many of them — though not all — are probably competing for the same jobs. To improve your chances of scoring the next great gig, it helps to know how recruiters use the site.
Recruiters scour the world’s most popular professional networking site looking for the perfect candidate, but there’s a lot they do before they even get to your profile page. Some 93{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of hiring managers search LinkedIn LNKD, -0.36{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} for recruits, according to a 2013 survey by career website Jobvite; 65{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} search Facebook FB, +1.24{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and 55{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} consult Twitter TWTR, +0.85{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} accounts. Another 18{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of recruiters search Google+ GOOG, +1.45{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and, in case there are any homemade videos lurking about, 15{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} will type your name into YouTube. Rule No. 1: “Your LinkedIn profile should be public,” says Jenny Foss, president of the Ladder Recruiting Group in Portland, Ore.
U.S. adds 288,000 jobs as winter lull fades
Americans gained jobs at the fastest pace in more than two years last month and the jobless rate plunged to 6.3{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}, a sign the economy has rebounded from a winter rut.
Most people spend so much time crafting their pitch, they forget about how they appear in a search result. “It’s the first thing that recruiters look at,” says Nicole Greenberg Strecker, managing director of recruitment agency STA Worldwide in Chicago, Ill. Your bio should include title, industry and location. “If you want to work in Silicon Valley and live in Kansas, change your location to Silicon Valley on LinkedIn. Recruiters search zip codes.” And the title should be razor-sharp. “Don’t write senior analyst at Ernst & Young, write hedge fund financial analyst at Ernst & Young,” says Jeremy Roberts, editor of Sourcecon, a blog and conference series for recruiters.
Recruiters punch in keywords, not buzzwords. When fine-tuning their initial search to find high-performing candidates, for instance, they’ll look for terms like “won,” “sold,” “achieved,” “built” and “president’s club.” No software is too old to mention. Technology recruitment consultants look for people who are proficient in WordPress because many companies don’t have the latest programs, Roberts says. And if you use in-demand open-sourced software like Ruby on Rails, say so. “It will save you a lot of spam,” he says; recruiters also recoil at buzzwords like “maven,” “guru,” “prophet” and “ninja” (unless you’re a black belt or a mutant turtle).
Leave a trail of virtual crumbs that lead to your profile. Hiring professionals lurk within LinkedIn industry groups and blogs, says Tamryn M. Hennessy, a vice president of career services at Rasmussen College. “Join them, especially if you want to change industries,” she says. “It’s a tremendous way to get smart about an industry and get on a recruiter’s radar.” Take part in the conversation, Hennessy adds, but only if you have something to say. Beware of criticism, says Piera Palazzolo, senior vice president for marketing at Dale Carnegie Training. “Never complain or express sour grapes,” she says. “It’s not Facebook (FB), it’s a professional network.”
Once they arrive on your page, you want to keep them there. “LinkedIn is speed dating for professionals,” says Grace Killelea founder and CEO of Half The Sky Women’s Leadership Institute. Recruiters are looking for reasons not to court you and anything that appears odd will be a red alert. “If there are gaps in your work history, fill that in, otherwise recruiters are going to get nervous,” she says. “Many people who were laid off are not comfortable filling in those gaps, but they absolutely need too.” Include details of volunteer work or, if it’s true, add “consulting,” she adds. Killelea’s golden rule for LinkedIn (and life): “If you can’t hide it, decorate it.”
Older job-seekers need to walk a fine line. Unless you made the cover of “Time” or discovered a solar galaxy, experience has a shelf life on LinkedIn, says Scott Dobroski, career trends analyst at Glassdoor. There’s no need to wax lyrical about a job that’s more than 10 years old, he says. And those who graduated from college a decade ago may want to exclude the date they graduated. “Your college graduation date will age you,” he says, “and although ageism is illegal, it’s happening all the time.” On the other hand, if you’re applying for a job as CEO of a Fortune 500 company and you graduated in 1986, it’s okay to leave the date, Dobroski says.
Most recruiters won’t care whether you have 1,000 endorsements, experts say. They’re regarded as the confetti of the digital world: Scattered too randomly and, as such, they lose meaning. Recruiters are actually looking for thoughtful recommendations from a well-respected peer or former employer, Palazzolo says. “I get endorsed for things that I don’t know how to do,” she says. “People want to see you’ve developed solid relationships.” That said, Foss says people should manage their skills and endorsements, rather than letting other people choose them, and an endorsement from a very big name could help.
Employers will also try to gauge your personality from your presentation. There’s a fine line between arrogance and confidence, Roberts says. Some tips: “Don’t put you’re a member of Mensa,” he says. “People have to seek out Mensa membership. Most hiring managers don’t want to hire someone who’s smarter than them.” But it’s smart to write, “increased conference attendance by 40{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce},” instead of a passive job description like, “conference manager.” People don’t want to read a LinkedIn profile that resembles a self-published memoir. “Don’t pompously refer to yourself in the third person,” Foss adds.
Recruiters assess photos differently, depending on the industry, says Killelea. Only include your dog if you’re a dog walker or dog groomer, she adds. Photos over two years old should be updated, she says. Selfies are a no-no, says Tim Sackett, president of HRU Technical Resources, an information technology and engineering staffing firm in Lansing, Mich. “Ask yourself, “If my grandmother looked at this picture, would she be proud?’” Sackett has seen LinkedIn photos of a woman dressed in an American flag and a man in blurry selfie taken in his bedroom.
- Published in Blog
Here are the most and least expensive states to live in the U.S.
(Updates with link to most and least expensive cities to live in the U.S.)
For the first time, the Commerce Department’s Bureau of Economic Analysis released price-adjusted estimates of personal income for states and metropolitan areas for 2008 to 2012, and it shows that, at the very least, it’s more expensive for Members of Congress to live in the nation’s capital on their $174,000 salary than in any state from which they hail.
The results show the District of Columbia, in 2012, had the highest “regional price parity” of any state. Granted, D.C.’s really a city, not a state, and set against their more natural comparisons, it ranks fifth, behind the Urban Honolulu area, New York-Newark-Jersey City, San Jose-Sunnyvale-Santa Clara, Bridgeport-Stamford-Norwalk and San Francisco-Oakland-Hayward. Beaches, hedge funds and technology are the key to prices, evidently.
The cheapest metro areas, by this methodology, were Danville, Ill.; Jefferson City, Mo.; Jackson, Tenn.; Jonesboro, Ark.; and Rome, Ga.
See related look at most and least expensive cities to live in the U.S.
Put another way,it costs 54{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} more to live in Honolulu than in Danville.
The top five states (outside of D.C.) were Hawaii, New York, New Jersey, California and Maryland, and the bottom five states were Mississippi, Arkansas, Alabama, Missouri and South Dakota. So, it costs 36{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} more to live in Hawaii than in Mississippi.
The BEA says it produced the report in large part so people and businesses can have a better understanding how their personal income may be impacted by a job change or move. There is regional consumer price index data, but those statistics aren’t designed for regional or city comparisons, whereas this data is, a spokesman says.
- Published in Blog